Express News | Lexaria Bioscience Announces Progress In Human Pilot Study GLP-1-H24-2; Second Round Of Dosing Completed For All Nine Participants, Final Arm Expected To Finish By Early July
Express News | Lexaria Bioscience Corp: Expects to Complete Third (Final) Arm of Study in Early July
Express News | Lexaria Bioscience Corp: Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study
Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Healthequity Inc (NASDAQ:HQY) rose sharply in today's pre-market trading as the company reported better-than-expected first-quarter financial results.The company reported quarterly earnings
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersCue Health (NASDAQ:HLTH) shares rose 70.1% to $0.09 during Thursday's regular session. The market value of their outstanding shares is at $14.8 million. OneMedNet (NASDAQ:ONMD) shares increased
Lexaria Awards Contract To A CRO To Perform The Co's Human Pilot Study #3, Which Will Evaluate A Dual Action GLP-1 + GIP
First-ever DehydraTECH-processed tirzepatide from Zepbound to be tested in a swallowed oral formatKELOWNA, BC / ACCESSWIRE / May 23, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "C
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Lexaria Bioscience (LEXX) and Guardant Health (GH)
Express News | Lexaria Granted Patent #21: Compositions and Methods for Treating Hypertension And #24: Compositions and Methods for Treating Epilepsy
Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy
The Company has received a new granted patent in Lexaria's patent family #21: Compositions and Methods for Treating Hypertension.
Express News | Lexaria Bioscience Shares Are Trading Higher After the Company Announced It Has Began Dosing in Its GLP-1 Animal Study
Express News | Lexaria Bioscience Begins Dosing In GLP-1 Animal Study
Here's Why We're Watching Lexaria Bioscience's (NASDAQ:LEXX) Cash Burn Situation
Express News | Lexaria Bioscience: Human Pilot Study #2, GLP-1-H24-2 Underway & First Dosing Visit for All Nine Study Participants Has Already Concluded
Express News | Lexaria Bioscience Corp: Begins Dosing of Its Second GLP-1 Human Pilot Study
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
KELOWNA, BC / ACCESSWIRE / May 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that human pilot stu
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs
KELOWNA, BC / ACCESSWIRE / May 6, 2024 / Lexaria Bioscience Corp. , a global innovator in drug delivery platforms announces an applied research
Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance
KELOWNA, BC / ACCESSWIRE / April 30, 2024 / Lexaria Bioscience Corp. , a global innovator in drug delivery platforms announces it has entered
Lexaria Bioscience, Biosig Technologies, BIMI Holdings Among Healthcare Movers
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersClene (NASDAQ:CLNN) shares moved upwards by 54.9% to $0.48 during Tuesday's after-market session. The company's market cap stands at $61.6 million. Talphera (NASDAQ:TLPH) shares moved upwards b
Express News | Lexaria Bioscience - Subject Recruitment to Begin Immediately & Co to Announce as Soon as First Dosing Has Begun, Expected Within 30 Days or Less
No Data